The Estimate of Interferon-inducible Protein-10 and Interferon-γ in Hemodialysis Patients with Chronic HCV

Authors

  • Mahmood Abdujabar Altobje Department of Biology, College of Science, University of Mosul, Mosul, Iraq
  • Zeyad Thanoon Al-Rrassam Department of Biophysics, College of Science, University of Mosul, Mosul, Iraq

DOI:

https://doi.org/10.3889/oamjms.2021.7030

Keywords:

Alkaline phosphatase, CXCL-10, HCV, Hemodialysis, Interferon

Abstract

BACKGROUND: Due to the rise in the number of deaths, the hepatitis C virus remains a public health issue worldwide. During the recovery period, cytokines are known as indicators of chronic liver infection.

AIM: In this study, immunological parameters were measured and calculated in chronic hemodialysis patients after more than 6 months of drug administration.

METHODS: We have picked 60 patients with hemodialysis who are anti-HCV positive. ELISA and the calculation of alkaline phosphatase (ALP) were used to evaluate IP-10 and IFN-γ.

RESULTS: A substantial association between variables and infected cases was found. No worth was considered for genders or age categories.

CONCLUSIONS: The serum IP-10 level can be a warning primarily for patients who have taken a variety of prescriptions intermittently. In both the RPT and RST cohorts, IFN-γ serum levels are usually elevated. Serum level ALP is not a particular chronic HCV predictor.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Plum Analytics Artifact Widget Block

References

Lu MY, Huang CI, Dai1CY, Wang SC, Hsieh MY, Hsieh MH, et al. Elevated on-treatment levels of serum IFN-gamma is associated with treatment failure of peginterferon plus ribavirin therapy for chronic hepatitis C. Sci Rep. 2016;6:22995. PMid:26965318 DOI: https://doi.org/10.1038/srep22995

Etik D, Ocal S, Boyacioglu A. Hepatitis C infection in hemodialysis patients: A review. Hepatology. 2015;7(6):885-95. https://doi.org/10.4254/wjh.v7.i6.885 PMid:25937865

Vigani A, Pavan M, Tozzo R, Gonçales E, Lazarini M, Oliveira A, Gonçales F. Extended treatment with interferon and ribavirin in a hemodialysis patient with chronic hepatitis C. Case Report. 2009;21:93-5. https://doi.org/10.4254/wjh.v7.i6.885 DOI: https://doi.org/10.4254/wjh.v7.i6.885

Yu YC, Wang Y, He CL, Wang MR, Wang YM. Management of hepatitis C virus infection in hemodialysis patients. Hepatology. 2014;6(6):419-25. https://doi.org/10.4254/wjh.v6.i6.419 PMid:25018852 DOI: https://doi.org/10.4254/wjh.v6.i6.419

Brownell J, Polyak S. Molecular pathways: Hepatitis C virus, CXCL10, and the inflammatory road to liver cancer. Clin Cancer Res. 2013;19(6):1347-52. https://doi.org/10.1371/journal.pone.0023856 PMid:23322900 DOI: https://doi.org/10.1158/1078-0432.CCR-12-0928

Tsuge M, Fujimoto Y, Hiraga N, Zhang Y, Ohnishi M, Kohno T, et al. Hepatitis C virus infection suppresses the interferon response in the liver of the human hepatocyte chimeric mouse. Plos One. 2011;6(8):e23856. https://doi.org/10.4254/wjh.v6.i6.419 PMid:21886832 DOI: https://doi.org/10.1371/journal.pone.0023856

Barakat A, Hegazy A, Farag R, Abdul Baky A, Arafa L, Farouk A. Role of interferon-gamma and immune response biomarkers in predicting IFN-alpha responsiveness and treatment outcome in patients with Hepatitis C virus. Int J Virol. 2012;8(4):288-98. https://doi.org/10.1172/JCI40594 DOI: https://doi.org/10.3923/ijv.2012.288.298

Casrouge A, Decalf J, Ahloulay M, Lababidi C, Mansour H, Vallet-Pichard A, et al. Evidence for an antagonist form of the chemokine CXCL10 in patients chronically infected with HCV. J Clin Investigation. 2011;121(1):308-17. https://doi.org/10.1172/JCI40594 PMid:21183794 DOI: https://doi.org/10.1172/JCI40594

Mascia C, Vita S, Zuccalà P, Marocco R, Tieghi T, Savinelli S, et al. Changes in inflammatory biomarkers in HCV infected patients undergoing direct-acting antiviral-containing regimens with or without interferon. PLoS One. 2011;3:1-14. https://doi.org/10.1002/hep.21011

Miyaki E, Hiraga N, Imamura M, Uchida T, Kan H, Tsuge M, et al. Interferon-alpha treatment stimulates interferon-gamma expression in Type I NKT cells and enhances their antiviral effect against Hepatitis C virus. PLoS One. 2017;2:1-2. https://doi.org/10.1016/j.ekir.2017.04.003 PMid:28253324

Caragea D, Mihaliovici A, Streba C, Schenker M, Ungureanu B, Caragea I, et al. Hepatitis C infection in hemodialysis patients. Curr Health Sci J. 2017;44(2):107-12. https://doi.org/10.1371/journal.pone.0172412 PMid:30746156 DOI: https://doi.org/10.1371/journal.pone.0172412

Romero AI, Lagging M, Westin J, Dhillon AP, Dustin LB, Pawlotsky JM. Interferon (IFN)-gamma inducible protein-10: Association with histological results, viral kinetics, and outcome during treatment with pegylated IFN-alpha 2a and ribavirin for chronic Hepatitis C virus infection. J Infect Dis. 2006;194(7):895-903. https://doi.org/10.1086/507307 PMid:16960776 DOI: https://doi.org/10.1086/507307

Omran D, Hamdy S, Tawfik S, Esmat S, Saleh D, Zayed R. Association of Interferon-γ inducible protein-10 pretreatment level and sustained virological response in HCV-positive Egyptian patients. Ann Clin Lab Sci. 2014;44(2):167-72. PMid:24795055

Crisan D, Grigorescu M, Radu C, Suciu A, Grigorescu M. Interferon-γ-inducible protein-10 in chronic Hepatitis C: Correlations with insulin resistance, histological features and sustained virological response. Indian J Med Res. 2017;145(4):543-50. https://doi.org/10.4103/ijmr.IJMR_1410_14 PMid:28862188

Huang Y, Chen X, Konduri M, Fomina N, Lu J, Jin L, et al. Mechanistic link between the anti-HCV effect of interferon gamma and control of viral replication by a Ras-MAPK signaling cascade. Hepatology. 2006;43(1):81-90. https://doi.org/10.1002/hep.21011 PMid:16374867 DOI: https://doi.org/10.1002/hep.21011

Shin EC, Protzer U, Untergasser A, Feinstone S, Rice S, Hasselschwert D, et al. Liver-directed gamma interferon gene delivery in chronic Hepatitis C. J Virol. 2005;79(21):13412-20. https://doi.org/10.1128/JVI.79.21.13412-13420.2005 PMid:16227262 DOI: https://doi.org/10.1128/JVI.79.21.13412-13420.2005

Khedmat H, Amini M, Ghamar-Chehreh M, Agah S. Hepatitis C virus infection in dialysis patients. Saudi J Kidney Dis Transpl. 2014;25(1):1-8. https://doi.org/10.4103/1319-2442.124455 PMid:24434375 DOI: https://doi.org/10.4103/1319-2442.124455

Agarwal S, Bagchi S, Yadav R. Hemodialysis patients treated for Hepatitis C using a sofosbuvir-based regimen. Kidney Int Rep. 2017;2(5):831-5. https://doi.org/10.1016/j.ekir.2017.04.003 PMid:29270489 DOI: https://doi.org/10.1016/j.ekir.2017.04.003

Dawood A, Khaleel A, Hayawi A. Estimate viral RNA of hepatitis C of β-thalassemia patients in Nineveh province. EJMCM. 2020;7(10):1-8.

Dawood A, Altobje M, Al-Rrassam Z. Adoption of Euvax-B vaccine in Nineveh. VacciMonitor. 2021;30(2):91-5.

Downloads

Published

2021-10-09

How to Cite

1.
Altobje MA, Al-Rrassam ZT. The Estimate of Interferon-inducible Protein-10 and Interferon-γ in Hemodialysis Patients with Chronic HCV. Open Access Maced J Med Sci [Internet]. 2021 Oct. 9 [cited 2024 Apr. 12];9(A):928-33. Available from: https://oamjms.eu/index.php/mjms/article/view/7030